Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Public ClinicalTrials.gov record NCT00106353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors
Study identification
- NCT ID
- NCT00106353
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Interventions
- Torisel Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2005
- Primary completion
- Sep 30, 2009
- Completion
- Dec 31, 2011
- Last update posted
- Feb 7, 2013
2005 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | San Francisco | California | 94143 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60614 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46202 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | New York | New York | 11021 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104-4318 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29605 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38105-2794 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-2399 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00106353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00106353 live on ClinicalTrials.gov.